文献速递前列腺癌前列腺增生与排尿功能障碍

机器人水刀切除术治疗伴有下尿路症状的前列腺癌男性

Robotic Waterjet Resection for Men With Prostate Cancer Suffering From Lower Urinary Tract Symptoms.
PubMed 文献 · Urology · 2025-01-14

这项前瞻性研究纳入活检阳性且mpMRI可见病灶(PIRADS≥3)并接受Aquablation的男性,评估循环肿瘤细胞(CTC)变化。术后IPSS降低、SHIM与MSHQ-EjD稳定或改善,CTC在术后即刻短暂升高、2天内回落,未见不良事件,6个月时基线mpMRI病灶均不可见且活检无分级组进展。

要点

  • Aquablation后IPSS降低,SHIM与MSHQ-EjD稳定或改善,未报告尿失禁、勃起功能障碍、射精功能障碍或直肠毒性。
  • CTC可检出比例术前80%、术后即刻100%、术后第2天20%、术后第7天60%,CTC短暂升高持续<2天。
  • 6个月随访时基线mpMRI病灶均不可见,活检未显示分级组进展。

核心结论

  • 在主动监测人群中,Aquablation改善排尿功能、稳定或改善性功能,CTC短暂升高持续<2天且未引起肿瘤学担忧。
  • 作者认为Aquablation可考虑作为因BPH需治疗下尿路症状的局限性前列腺癌男性的安全选择。

研究设计与样本

  • 前瞻性研究,纳入活检阳性且mpMRI可见病灶(PIRADS≥3)并接受Aquablation的受试者。
  • 术前、术中及术后采集10 mL血样,用免疫荧光法测定CTC计数。

主要发现

  • 受试者平均年龄63.4岁,基线PSA 8.9 ng/mL,前列腺体积60.3 mL。
  • 所有受试者IPSS评分降低,SHIM与MSHQ-EjD评分稳定或改善。
  • CTC可检出比例:术前80%,Aquablation后即刻100%,术后第2天20%,术后第7天60%。
  • 每例患者10 mL血中平均CTC数:术前1.2,术后即刻3.2,第2天0.2,第7天1.0。
  • 前列腺体积在3个月和6个月显著减小,PSA水平相应降低;未报告不良事件,未观察到尿失禁、勃起功能障碍、射精功能障碍或直肠毒性。

临床怎么用

  • 作者认为Aquablation可考虑用于因BPH需治疗下尿路症状的局限性前列腺癌男性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of Aquablation on circulating tumor cells (CTCs) in men with localized prostate cancer. METHODS: This prospective study included subjects with biopsy-positive mpMRI visible lesions (PIRADS ≥3) who underwent Aquablation. Ten mL blood samples were collected before, during and after the procedure to measure CTC counts using an immunofluorescence assay. RESULTS: The mean age of participants was 63.4 years, with a baseline PSA of 8.9 ng/mL and a prostate volume of 60.3 mL. All subjects experienced reduced IPSS scores and stable or improved SHIM and MSHQ-EjD scores. Detectable CTCs were found in 80% of subjects before Aquablation, 100% immediately after Aquablation, 20% on post-op day 2, and 60% on post-op day 7. The mean number of CTCs per patient 10 mL blood draw was 1.2 preoperatively, 3.2 immediately post-op, 0.2 on day 2, and 1.0 on day 7. Prostate volumes decreased significantly at 3 and 6 months, with corresponding reductions in PSA levels. There were no adverse events reported. Specifically, no instances of incontinence, erectile dysfunction, ejaculatory dysfunction, or rectal toxicity were observed. At 6-month follow-up, all baseline mpMRI lesions were no longer visible on mpMRI and follow-up biopsies showed no grade group progression. CONCLUSION: In an active surveillance population, Aquablation resulted in improved urinary function, stable or improved sexual function, and a transient spike in CTCs lasting <2 days that did not result in any oncologic concern. Aquablation may be considered a safe option for men with localized prostate cancer who require treatment for LUTS due to BPH.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Teoh JYC, Yuen SKK, Lau BSY, et al. Robotic Waterjet Resection for Men With Prostate Cancer Suffering From Lower Urinary Tract Symptoms. Urology. 2025. PMID: 39818305. doi:10.1016/j.urology.2025.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。